Histone methylases as novel drug targets: developing inhibitors of EZH2

Catherine Baugé (1, 2) , Céline Bazille (3, 2, 1) , Nicolas Girard (2, 1) , Eva Lhuissier (2, 1) , Karim Boumediene (2, 1)

1 BioConnecT - Microenvironnement et Pathologies du Cartilage
2 NU - Normandie Université
3 Laboratoire d'Anatomie Pathologique [CHU Caen]

Post-translational modifications of histones (so-called epigenetic modifications) play a major role in transcriptional control and normal development, and are tightly regulated. Disruption of their control is a frequent event in disease. In particular, the methylation of lysine 27 on histone H3 (H3K27), induced by the methylase EZH2, emerges as a key control of gene expression and a major regulator of cell physiology. The identification of driver mutations in EZH2 has already led to new prognostic and therapeutic advances, and new classes of potent and specific inhibitors for EZH2 show promising results in preclinical trials. This review examines the roles of histone lysine methylases and demethylases in cells and focuses on the recent knowledge and developments about EZH2.

Domaines: Cancer; Biologie moléculaire; Sciences du Vivant [q-bio]

Catherine Baugé, Céline Bazille, Nicolas Girard, Eva Lhuissier, Karim Boumediene. Histone methylases as novel drug targets: developing inhibitors of EZH2. Future Medicinal Chemistry, 2013, 6 (17), pp.1943-65. ⟨10.4155/fmc.14.123⟩. ⟨hal-01147761⟩